Key highlights

  • Syntara shares were down 28.95% at $0.014 during the 10 November 2026 trading session.
  • The company has paused recruitment in the Phase 1b study of SNT-9465 after reports of mild to moderate skin irritation.
  • Syntara expects to complete its review of the study data within the current quarter.

Shares in clinical-stage drug developer Syntara Ltd (ASX:SNT) came under heavy selling pressure during the Trading session on 10 November 2026, slipping 28.95% to $0.014. The move stood in sharp contrast to the broader market, with the S&P/ASX 200 higher by 1.34%, or 121.20 points, at 9,150.90. Syntara focuses on extracellular matrix dysfunction and draws on its amine oxidase chemistry expertise to develop its pipeline. The latest update arrived the same day, when the company announced that it had paused recruitment in its Phase 1b study of topical SNT-9465 in patients with hypertrophic sternotomy scars.

Recruitment paused in the SNT-9465 study (10 November 2026)

Syntara said on 10 November 2026 that it had halted new enrolment in the Phase 1b trial of SNT-9465, a topical panlysyl oxidase inhibitor. The decision followed an internal review of local tolerability findings from the blinded study population.

The company said it had received reports of mild to moderate skin irritation in some patients. Recruitment will stay paused while the team reviews unblinded data from both completed and ongoing participants. Once that review is finished, Syntara will decide whether to restart recruitment or discontinue the study altogether.

Timing of the review and recent study expansion

Before the pause, Syntara had expanded recruitment and opened an additional clinical site to keep the study on schedule. The company now says the tolerability issues that emerged in the blinded population require a pause so that the available data can be analysed in full.

Syntara expects the review to be completed within the current quarter. The company has said it will analyse all collected data to understand the potential of this therapeutic approach.

Sector context

Clinical-stage drug developers typically depend on trial milestones, and shares in companies at this stage often move sharply on news about safety, enrolment or study design. Investors in the sector tend to focus on how trial results compare with expectations and whether a company can keep its development timelines on track. Syntara's share price has been trading at a few cents, a level where small changes in sentiment can translate into large percentage moves.

Risks

The most immediate risk is the tolerability signal itself. Skin irritation reports in a Phase 1b study could lead to protocol changes, a longer timeline or a decision to stop the program. The outcome of the unblinded review is not yet known, and the company has made clear that either path remains open.

Development timelines for early-stage drug programs are also subject to change, and any delay could affect how the company plans its next steps.

What to watch ahead

The main event on the calendar is the completion of the unblinded data review, which Syntara expects this quarter. Investors will be looking for whether recruitment restarts, whether the study is modified, or whether it is discontinued. Any further update on tolerability findings will also be closely followed.

Final Word

Syntara's share move during the 10 November 2026 session reflects a sharp reaction to a pause in its SNT-9465 study. The company's next update, expected after its unblinded data review, will determine the path of the program.